Grace Therapeutics, Inc. 8-K Report: Major Updates on February 10, 2025
Based on the provided section of the financial report, here are the key pieces of information extracted:
- Entity Information:
- Company Name: Grace Therapeutics, Inc.
- CIK: 0001444192
- State of Incorporation: Delaware (DE)
- SEC File Number: 001-35776
- EIN: 98-1359336
- Address: 103 Carnegie Center, Suite 300, Princeton, NJ 08540
- Contact Number: 609-322-1602
- Filing Type:
- Form Type: 8-K (current report to announce major events that shareholders should know about)
- Filing Date:
- Date: February 10, 2025
- Equity Information:
- Security Type: Common Stock
- Par Value: $0.0001 per share
- Ticker Symbol: GRCE
- Exchange: NASDAQ
- Period of Report:
- Start Date: February 10, 2025
- End Date: February 10, 2025
Insights:
- The report indicates that Grace Therapeutics, Inc. is a publicly traded company listed on NASDAQ under the ticker symbol GRCE.
- The usage of Form 8-K suggests that the company may have undergone significant events that warrant immediate disclosure to the public, though the actual content of the 8-K filing is not provided in this snippet.
- The specific date of the filing aligns with the reporting period, indicating that this report might serve to inform stakeholders about an event occurring on that exact date.
This information could be critical for investors and stakeholders interested in the company's latest developments and corporate actions.